Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Centocor's Latest Warning For Remicade Called 'Non-Event'

Aug. 27, 2004

By Aaron Lorenzo

SIGA's Biodefense Research Gets Commitments For $12M

Aug. 26, 2004

By Aaron Lorenzo

SIGA's Biodefense Research Gets Commitments For $12M

Aug. 26, 2004

By Aaron Lorenzo

More Data Analysis Helps Shape Amarin's Miraxion Phase III Plans

Aug. 25, 2004

By Aaron Lorenzo

More Data Analysis Helps Shape Amarin's Miraxion Phase III Plans

Aug. 25, 2004

By Aaron Lorenzo

More Data Analysis Helps Shape Amarin's Miraxion Phase III Plans

Aug. 25, 2004

By Aaron Lorenzo

More Data Analysis Helps Shape Amarin's Miraxion Phase III Plans

Aug. 25, 2004

By Aaron Lorenzo

ViroPharma Sheds Pleconaril; Deal Potentially Worth $75M

Aug. 24, 2004

By Aaron Lorenzo

ViroPharma Sheds Pleconaril; Deal Potentially Worth $75M

Aug. 24, 2004

By Aaron Lorenzo

Implantable Drug Firm Valera Gets $11.5M In Third Round

Aug. 23, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 10, 2025
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...
Australia’s Celosia heads toward clinic with gene therapy for ALS
BioWorld
After raising AU$16.75 million (US$10.4 million) in a series A round, Celosia Therapeutics Pty Ltd. is heading toward the clinic with its novel gene therapy that...
Sangamo stock plunges as Pfizer leaves hemophilia partnership
BioWorld
Sangamo Therapeutics Inc.’s stock sank sharply on the last day of 2025 as Pfizer Inc. handed back the rights to their collaborative gene therapy hemophilia A...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.